GlassScriptPhysician profile
Thomas Steen Trawick
NPI 1487652970
$2,831.93
in general payments reported to CMS, 2019-2025
22 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2023: $1,007 · 2024: $315 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $978 · Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $977.70 |
| Food and Beverage | $932.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,846.88 | 2019-2023 | Da Vinci Surgical System |
| Amgen INC. | $242.26 | 2024-2025 | Evenity, Otezla, Repatha |
| Lundbeck LLC | $104.09 | 2024-2025 | Rexulti, Vyepti |
| Ardelyx, INC. | $71.13 | 2024-2025 | Ibsrela |
| Axsome Therapeutics, INC. | $59.17 | 2025 | Auvelity |
| Antares Pharma, INC. | $55.32 | 2025 | Xyosted |
| Lilly USA, LLC | $53.27 | 2024-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $51.53 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Tolmar, INC. | $39.66 | 2025 | Jatenzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.00 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $31.53 | 2019-2024 | Lokelma |
| Ethicon US, LLC | $29.17 | 2023 | Megadyne |
| Recor Medical INC | $28.34 | 2025 | Paradise Ultrasound Renal Denervation System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.21 | 2025 | Caplyta |
| Gilead Sciences, INC. | $23.24 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $22.62 | 2024 | Quviviq |
| Cvrx, INC. | $22.60 | 2024 | Barostim Neo System |
| Phathom Pharmaceuticals, INC. | $20.35 | 2025 | Voquezna |
| Pfizer INC. | $19.85 | 2025 | |
| Itamar Medical INC | $18.50 | 2024 | Watchpatone |
| Janssen Pharmaceuticals, INC | $16.71 | 2019 | |
| Abbvie INC. | $14.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Trawick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.